Aurobindo Pharma Delivers Strong Q2FY27 Results with Record Revenue and Margins
Aurobindo Pharma Ltd · Investor Presentation · 05 Nov 2026, 1:35 am
Aurobindo Pharma Delivers Strong Q2FY27 Results with Record Revenue and Margins Aurobindo Pharma reported its highest-ever quarterly revenue of ₹10,263 Cr in Q2FY27, up 23.9% YoY and 12.2% QoQ, driven by solid formulation growth across the US (+25.2% YoY) and Europe (+27.5% YoY). EBITDA reached a record ₹2,156 Cr (+28.5% YoY) with margins expanding 75 bps YoY to 21.0%, while PAT rose 32.5% YoY to ₹1,124 Cr. The company completed the Lannett acquisition, generated US$ 146mn in net cash flow, and maintained a net cash position of ~US$ 189mn as of 30th Sep'26.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. · 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. · 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". · 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. · 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. · 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. · 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. · 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. · 05 Nov 2026
